Day2, July 6, 9:00 a.m. Plenum Keynote and Morning-Panel
Current Role: Clemens Wendtner, MD, is Professor of Medicine and Chief Physician at Munich Clinic Schwabing, an academic hospital of the Ludwig-Maximilian University (LMU) of Munich.
Clinical Focus & Interest: Prof. Wendtner has been principal investigator for numerous phase I-III clinical studies, and his scientific interests focus on development of new therapies in the field of chronic lymphocytic leukemia (CLL). Furthermore, he is a specialist in infectious diseases with special focus on COVID-19.
Experience: Prof. Wendtner completed his MD qualification at the University of Münster, Germany, in 1993. Thereafter, he received a postdoctoral training at the Max-Planck-Institute in Martinsried, Germany, and at the National Institutes of Health (NIH), Bethesda, MD, until 1995. Following a clinical fellowship at LMU, he gained his German and US license in Internal Medicine before specializing as a hematologist and oncologist at the same institution. Prof. Wendtner received his postdoctoral lecture qualification at LMU in 2002 and received his Full Professorship of Medicine at the University of Cologne in 2004. He was Deputy Director of the Department of Hematology and Oncology at the University of Cologne until 2011. Since 2011 he is Chief Physician of the Department of Hematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine at the Munich Clinic Schwabing, an academic teaching hospital of the Ludwig-Maximilian University in Munich. During the COVID-19 pandemic, he has treated the first German patients with COVID-19 in his centre and acted as consultant for the National Academy of Sciences (Leopoldina) and the Federal as well as the Bavarian Ministry of Health. Prof. Wendtner is an auditor in internal medicine, hematology/oncology at the Bavarian Chamber of Physicians in Munich (since 2011) and an expert for benefit assessment of oncology drugs at the Federal Joint Committee in Berlin (since 2015).
Affiliations: As a founding member of the German CLL Study Group (GCLLSG), Prof. Wendtner participates on the Steering Committee and is the GCLLSG’s Secretary. He has published more than 200 articles in peer-reviewed journals including NEJM, Cell, Nature, Lancet, Blood, and others. Since 2019, he is Deputy Director of the Scientific Ethics committee of LMU.